Kymera Therapeutics (NASDAQ: KYMR)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-05 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.660 | -0.710 | -0.0500 | ||||
REV | 16.230M | 9.622M | -6.608M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Kymera Therapeutics (NASDAQ: KYMR) through any online brokerage.
Other companies in Kymera Therapeutics’s space includes: Chinook Therapeutics (NASDAQ:KDNY), Syndax Pharmaceuticals (NASDAQ:SNDX), Replimune Group (NASDAQ:REPL), FibroGen (NASDAQ:FGEN) and Arcutis Biotherapeutics (NASDAQ:ARQT).
The latest price target for Kymera Therapeutics (NASDAQ: KYMR) was reported by Wells Fargo on Wednesday, June 1, 2022. The analyst firm set a price target for 35.00 expecting KYMR to rise to within 12 months (a possible 68.84% upside). 13 analyst firms have reported ratings in the last year.
The stock price for Kymera Therapeutics (NASDAQ: KYMR) is $20.73 last updated June 27, 2022, 8:00 PM UTC.
There are no upcoming dividends for Kymera Therapeutics.
Kymera Therapeutics’s Q2 earnings are confirmed for Friday, August 5, 2022.
There is no upcoming split for Kymera Therapeutics.
Kymera Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.